June 13, 2017 Special Meeting of OncoGenex Stockholders to Vote on Proposed Merger Scheduled for August 1, 2017 MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, June 13, 2017 /CNW/ — Achieve Life Sciences, Inc. (Achieve) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (OncoGenex) today announced that the Registration Statement on Form S-4 has been…
/Read More
March 8, 2017 Professor Nancy Rigotti, MD, will chair a symposium entitled “Cytisine Update: Moving Research Forward Toward a Globally Affordable Tobacco Cessation Medication” Other presenters include Natalie Walker, PhD; David Shurtleff, PhD; SooHee Jeong, PhD; and Kamran Siddiqi, PhD. MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, March. 8, 2017 /PRNewswire/ — Achieve…
/Read More
March 1, 2017 Ongoing IND-enabling Non-clinical Program to Support the Use of Cytisine in Smoking Cessation Multiple Key Cytisine Development and Regulatory Milestones Expected in 2017 MILL VALLEY, Calif., BOTHELL, Wash. and VANCOUVER, British Columbia, March 1, 2017 /CNW/ — Achieve Life Science, Inc. (Achieve) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (OncoGenex) today announced a…
/Read More
March 8, 2017 Proposed Merger Will Create Clinical-Stage, Biopharmaceutical Company Focused on the Development and Commercialization of Cytisine for Smoking Cessation Multiple Clinical and Regulatory Milestones Expected in the Next 12-18 Months BOTHELL, Wash. and VANCOUVER, British Columbia and MILL VALLEY, Calif., Jan. 5, 2017 /CNW/ –OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) (“OncoGenex”), a publicly held…
/Read More